Sources of finance for commercialization Clause Samples

Sources of finance for commercialization. The first big customers to take up the system if it works well are the two participating end- user organizations ORBIS and MRPS. Both are working close with insurance companies for the provision of elderly homecare. Already ORBIS is chosen by CZ, a big insurance company, as the Living Lab to test eHealth solutions. In this role ORBIS will in cooperation with CZ implement eHealth solutions and test them via a model developed by CZ and ORBIS together. In this model research for the eHealth solutions will be done for patient satisfaction, the care paths, clinical efficacy, organisational and care costs. For the eHealth solutions which have good outcomes based on this research, CZ will look for structural financing via the insurance. If Miraculous-Life is successful this can also be further tested via living lab cooperation between ORBIS and CZ. This can be a starting point of stimulating other insurances in other European countries in allocating budget for introducing the system in the elderly care process. The assumption that other organizations will be willing to invest in these developments, is also supported by findings of other projects in this area. Examples:  FlevoMind/Connected Vitality Network, a network aiming at remote support of elderly and psychiatric patients, was supported by CMO (‘Centre for social development’ in Flevoland, the Netherlands).  ▇▇▇▇▇▇▇, a virtual assistant (avatar) for agenda control (reminders of meetings and medicine), control of home automation, video calling with caregivers or relatives, etc., is supported by the province of Gelderland and the city of Deventer (both in the Netherlands).  GoOV is an app for assistance in using public transport. Local communities provide funding so that their citizens can get access to this tool.  Insurance company CZ has invested in care robot ‘Rose’, also in the Netherlands. This insurance company has dedicated funding (‘CZ Fonds’) for supporting such initiatives.  In the Netherlands it is becoming more common that the government or insurance companies pay for automation technology that enables elderly to live independently. Solutions such as a robotic arm or fall detection can even be part of the basic insurance if there is a medical indication22.  In Germany the most important deciding factor is the listing in the official aid catalogue (Hilfsmittelkatalog) of care insurance companies that is followed by all public insurers. In the last years various technical systems have been adde...
View SourceView Similar (2)
Sources of finance for commercialization. For each country represented by at least one partner within the project a list of organizations that may be interested in making use of the project outcome will be prepared. We will also investigate what the possibilities for funding for example by insurance companies can be. In case of a successful trial’s outcome, and provided the system meets the needs of residents, the first big customers to take up the system are the two participating end-user organizations ORBIS and MRPS. Those two are working close with insurance companies for the provision of elderly homecare. Already ORBIS, through its participation in other innovative research initiatives, has managed to achieve that a 3% (3.5 million Euro for 2013) of the yearly budget allocated from CZ, one of the biggest insurance companies in the Netherlands, to ORBIS to be used for carrying out research in the introduction of innovative technologies in elderly care reducing thus care cost in the next years. CZ has already agreed that in case of a successful Miraculous-Life trial a financial plan will be put in place for having the system being commercialized and taken up in the ORBIS homecare provision set-up. This can be a starting point of stimulating other insurances in other European countries in allocating budget for introducing the system in the elderly care process. The assumption that other organizations will be willing to invest in these developments, is also supported by findings of similar projects. Examples:  FlevoMind/Connected Vitality Network, a network aiming at remote support of elderly and psychiatric patients, was supported by CMO (‘Centre for social development in Flevoland, the Netherlands).  ▇▇▇▇▇▇▇, a virtual assistant (avatar) for agenda control (reminders of meetings and medicine), control of home automation, video calling with caregivers or relatives, etc., is supported by the province of Gelderland and the city of Deventer (both in the Netherlands).  GoOV is an app for assistance in using public transport. Local communities provide funding so that their citizens can get access to this tool.  Insurance company CZ has invested in care robot ‘Rose’, also in the Netherlands.
View Source
Sources of finance for commercialization. In case of a successful trial’s outcome the first big customers to take up the system are the two participating end-user organizations ORBIS and MRPS. Those two are working close with insurance companies for the provision of elderly homecare. Already ORBIS, through its participation in other innovative research initiatives, has managed to achieve that a 3% (3.5 million Euro for 2013) of the yearly budget allocated from CZ, the biggest Insurance companies in the Netherlands, to ORBIS to be used for carrying out research in the introduction of innovative technologies in elderly care reducing thus care cost in the next years. CZ has already agreed that in case of a successful Miraculous-Life trial a financial plan will be put in place for having the system being commercialized and taken up in the ORBIS homecare provision setup. This can be a starting point of stimulating positively other insurances in other European countries in allocating budget for introducing the system in the elderly care process
View Source

Related to Sources of finance for commercialization

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Technology Research Analyst Job# 1810 General Characteristics

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.